Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricGMABGenmab A/SABVXAbivax SAINCYIncyte
Snapshot
Price$33.65$116.74$128.31
Market cap$16.18B$11.63B$23.35B
Valuation
P/E20.9x—17.7x
Forward P/E27.9x—12.6x
Growth
Revenue growth20.7%—21.5%
EPS growth-25.3%—2455.3%
Profitability
Net margin21.1%—26.7%
ROE14.5%-51.7%29.2%
Balance sheet & cash
Debt / equity0.93x0x0.01x
Free cash flow yield—-2.1%2.2%
Dividend yield———
Verdict
Investment ratingFavorable· 62Weak· 35Strong· 86

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearGMABtoday $34ABVXtoday $117INCYtoday $128
2027$25.74 – $37.76+12% CAGR$93.68 – $137.40+18% CAGR$2,459.04 – $3,606.59+2711% CAGR
2028$26.26 – $38.51+7% CAGR$100.24 – $147.02+12% CAGR$62,836.06 – $92,159.56+2580% CAGR
2029$26.78 – $39.28+5% CAGR$107.26 – $157.31+10% CAGR$1,605,656.17 – $2,354,962.38+2538% CAGR
2030$27.32 – $40.07+4% CAGR$114.77 – $168.32+10% CAGR$41,029,492.63 – $60,176,589.19+2517% CAGR
2031$27.86 – $40.87+4% CAGR$122.80 – $180.11+9% CAGR$1,048,430,728.12 – $1,537,698,401.25+2504% CAGR
5-yr CAGR-3.7% – 4.0%1.0% – 9.1%2312.4% – 2504.5%